NASDAQ:CLCD - (CLCD) Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$46.53
+0.30 (1.20%)
Get New (CLCD) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CLCD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CLCD

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for (CLCD) in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $46.53.

This chart shows the closing price for CLCD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in (CLCD). This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/23/2017BarclaysDowngradeOverweight ➝ Equal Weight$45.00N/A
1/18/2017BTIG ResearchSet Price TargetBuy$52.00N/A
1/18/2017William BlairDowngradeOutperform ➝ Market PerformN/A
1/18/2017Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$49.00 ➝ $46.50N/A
12/22/2016BTIG ResearchInitiated CoverageBuy$58.00N/A
12/15/2016BarclaysInitiated CoverageOverweight$45.00N/A
10/24/2016Stifel NicolausBoost Price TargetBuy$30.00 ➝ $40.00N/A
9/30/2016Piper Jaffray CompaniesSet Price TargetOverweight$36.00 ➝ $49.00N/A
(Data available from 9/24/2016 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/28/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/25/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/24/2021

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
(CLCD) logo
CoLucid Pharmaceuticals, Inc. is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company's lead product candidate, is an oral tablet for the acute treatment of migraine in adults. Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal pathway in the central nervous system (CNS). Lasmiditan is designed to penetrate the CNS and block the pathway that contributes to headache pain. It is developing IV lasmiditan for the acute treatment of headache pain associated with migraine in adults, to be used in emergency rooms and urgent care settings. The Company is conducting its Phase III randomized, double-blind, placebo-controlled clinical trial of lasmiditan.
Read More

Today's Range

Now: $46.53
Low: $46.53
High: $46.53

50 Day Range

MA: N/A

52 Week Range

Now: $46.53
Low: $5.26
High: $46.65

Volume

N/A

Average Volume

708,479 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of (CLCD)?

The following equities research analysts have issued reports on (CLCD) in the last year:
View the latest analyst ratings for CLCD.

What is the current price target for (CLCD)?

0 Wall Street analysts have set twelve-month price targets for (CLCD) in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for (CLCD) in the next year.
View the latest price targets for CLCD.

What is the current consensus analyst rating for (CLCD)?

(CLCD) currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CLCD.

How do I contact (CLCD)'s investor relations team?

(CLCD)'s physical mailing address is 222 3rd St, CAMBRIDGE, MA 02142-1102, United States. The biopharmaceutical company's listed phone number is +1-781-3652596. The official website for (CLCD) is www.colucid.com.